|
|
Biogen Inc (NASDAQ: BIIB) |
|
|
|
| |
BIIB's Revenue Growth by Quarter and Year
Biogen Inc 's Revenue results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| BIIB Revenue (in millions $) |
FY 2024 |
FY 2023 |
FY 2022 |
FY 2021 |
| IV Quarter |
December |
2,454.70
|
2,386.30
|
2,544.00
|
2,733.80
|
| III Quarter |
September |
2,465.80
|
2,530.30
|
2,508.50
|
2,778.90
|
| II Quarter |
June |
2,464.90
|
2,456.00
|
2,589.10
|
2,775.00
|
| I Quarter |
March |
2,290.50
|
2,463.00
|
2,531.80
|
2,694.00
|
| FY |
|
9,675.90
|
9,835.60
|
10,173.40
|
10,981.70
|
| BIIB Revenue fourth quarter 2024 Y/Y Growth Comment |
Biogen Inc reported Revenue growth of 2.87% year on year in the fourth quarter 2024, to $ 2,454.70 millions, this is lower than Biogen Inc 's recent average Revenue growth of 8.62%.
Looking into fourth quarter 2024 results within Biotechnology & Pharmaceuticals industry 5 other companies have achieved higher Revenue growth. While Biogen Inc ' s Revenue increase of 2.87% ranks overall at the positon no. 525 in the fourth quarter 2024.
|
| BIIB Revenue ( Y/Y Growth %) |
2024
|
2023 |
2022 |
2021 |
| IV Quarter |
December |
2.87 % |
-6.2 % |
-6.94 % |
-4.16 % |
| III Quarter |
September |
-2.55 % |
0.87 % |
-9.73 % |
-17.69 % |
| II Quarter |
June |
0.36 % |
-5.14 % |
-6.7 % |
-24.63 % |
| I Quarter |
March |
-7 % |
-2.72 % |
-6.02 % |
-23.78 % |
| FY |
|
-1.62 % |
-3.32 % |
-7.36 % |
-18.32 % |
BIIB Revenue (Quarter on Quarter Growth %) |
2024
|
2023 |
2022 |
2021 |
| IV Quarter |
December |
-0.45 % |
-5.69 % |
1.42 % |
-1.62 % |
| III Quarter |
September |
0.04 % |
3.03 % |
-3.11 % |
0.14 % |
| II Quarter |
June |
7.61 % |
-0.28 % |
2.26 % |
3.01 % |
| I Quarter |
March |
-4.01 % |
-3.18 % |
-7.39 % |
-5.56 % |
| FY (Year on Year) |
|
-1.62 % |
-3.32 % |
-7.36 % |
-18.32 % |
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 41.42 % |
8.62 % |
-22.17 % |
| (Sep. 30, 2014) |
|
(Sep 30 2021) |
|
|
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 41.42 % |
8.62 % |
-22.17 % |
| (Sep. 30, 2014) |
|
(Sep 30 2021) |
|
| Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024 |
Biogen Inc 's Q/Q Revenue Growth
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 80.67 % |
2.92 % |
-15.51 % |
| (March 31, 2004) |
|
|
| BIIB's IV. Quarter Q/Q Revenue Comment |
In the IV. Quarter 2024 Biogen Inc realized decrease in Revenue from the previous quarter by -0.45% to $ 2,454.70 millions, from $ 2,465.80 millions released in the previous reporting period.
As we evaluate present shortcoming at the IV. Quarter, we should presume, that frequently IV. Quarter 2024 results occur weaker in contrast to the third quarter,Most analysts mentioned.
Within Biotechnology & Pharmaceuticals industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Biogen Inc 's Revenue growth quarter on quarter, overall rank is 1745. |
|
|
|
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 80.67 % |
2.92 % |
-15.51 % |
| (March 31, 2004) |
|
|
| BIIB's IV. Quarter Q/Q Revenue Comment |
In the IV. Quarter 2024 Biogen Inc realized decrease in Revenue sequentially by -0.45% to $ 2,454.70 millions, from $ 2,465.80 millions released a quarter before.
When you evaluate current downturn in the quarter, you must presume, that usually IV. Quarter 2024 results occur softer relative to the quarter before,Most analysts said.
Within Biotechnology & Pharmaceuticals industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Biogen Inc 's Revenue growth quarter on quarter, overall rank is 1745. |
|
Biogen Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth |
12 Months Ending
(Dec 31 2024) |
12 Months Ending
(Sep 30 2024) |
12 Months Ending
(Jun 30 2024) |
12 Months Ending
(Mar 31 2024) |
12 Months Ending
(Dec 31 2023) |
| Cumulative Revenue 12 Months Ending |
$ 9,675.90 |
$ 9,607.50 |
$ 9,672.00 |
$ 9,663.10 |
$ 9,835.60 |
| Y / Y Revenue Growth (TTM) |
-1.62 % |
-3.86 % |
-3 % |
-4.37 % |
-3.32 % |
| Year on Year Revenue Growth Overall
Ranking |
# 568 |
# 538 |
# 786 |
# 2060 |
# 571 |
| Seqeuential Revenue Change (TTM) |
0.71 % |
-0.67 % |
0.09 % |
-1.75 % |
-1.58 % |
| Seq. Revenue Growth (TTM) Overall
Ranking |
# 525 |
# 462 |
# 666 |
# 1647 |
# 494 |
| Cumulative Revenue growth
Comment |
Biogen Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Sep 30 2024. If the fiscal year would end in Dec 31 2024, Biogen Inc 's annual Revenue decline would be -1.62% year on year to $9,676 millions.
In the Healthcare sector 53 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 538 to 568. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
41.42 % |
8.62 % |
-22.17 % |
|
|
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
41.42 % |
8.62 % |
-22.17 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 6 |
| Sector |
# 49 |
| S&P 500 |
# 525 |
|
| Cumulative Revenue growth
Comment |
Biogen Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Sep 30 2024. If the fiscal year would end in Dec 31 2024, Biogen Inc 's annual Revenue fall would be -1.62% year on year to $9,676 millions.
In the Healthcare sector 53 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 538 to 568. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
41.42 % |
8.62 % |
-22.17 % |
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
41.42 % |
8.62 % |
-22.17 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 6 |
| Sector |
# 49 |
| S&P 500 |
# 525 |
|
4.73%